20/05/2026
💊 Tofacitinib – A Targeted Oral Therapy Changing the Rules of Autoimmune Disease Treatment
Tofacitinib, commercially known as Xeljanz® or Tofacent, is a modern JAK inhibitor that works by blocking inflammatory signaling within immune cells, precisely reducing inflammation without indiscriminate immunosuppression.
🔬 Which Autoimmune Diseases Is It Used For?
✔️ Rheumatoid arthritis (especially active or methotrexate-resistant cases)
✔️ Psoriatic arthritis
✔️ Serum-negative arthritis
✔️ Ulcerative colitis
✔️ Immune-mediated urticaria (Uveitis) in selected cases
✔️ Other autoimmune diseases as assessed by the physician and based on the clinical presentation
💊 Usual Dosage
• 5 mg twice daily
Or
10 mg once daily (extended-release)
⚠️ The dosage may vary depending on the type of disease, age, liver and kidney function, and concomitant medications.
🌟 Why is it a great choice?
✅ Oral medication (an effective alternative to biologic injections)
✅ Relatively fast onset of action
✅ Positive effects on joints, skin, and gut
✅ Effectiveness comparable to biologic therapies in many cases
✅ Suitable for patients unresponsive to conventional treatment
📊 Disease control rates (based on large clinical trials)
🔹 Rheumatoid Arthritis (RA)
According to ORAL Solo – ORAL Scan – ORAL Strategy studies:
• ACR20: Approximately 60–70%
• ACR50: Approximately 35–45%
• Achieving Low Disease Activity or Remission (DAS28): 30–40% within 6–12 months
Efficacy similar to TNF inhibitors, especially after methotrexate failure.
🔹 Psoriatic Arthritis (PsA)
In the OPAL Broaden and OPAL Beyond studies:
• ACR20: 50–60%
• Significant improvement in skin (PASI75), tendinitis, and chilblains
• Significant improvement in function and quality of life (HAQ-DI)
🔹 Ulcerative Colitis
In the OCTAVE Induction & Maintenance studies:
• Clinical Response: 55–60%
• Clinical Latency: 30–40%
• Mucosal Healing: Approximately 30%
Effective even in patients who have failed biological therapies.
🔹 Serum-Negative Arthritis
• Significant improvement in pain, stiffness, and markers of inflammatory activity
• Use is selective and under the supervision of a specialist.
🔹 Immune Ophthalmitis
• Reduced frequency of attacks
• Reduced inflammatory activity
• Reduced dependence on corticosteroids
Off-label use in selected cases. ⚠️ Potential Side Effects
• Increased susceptibility to infections (especially shingles)
• Elevated cholesterol
• Elevated liver enzymes
• Decreased blood cell count
• Increased risk of blood clots at high doses or in the presence of risk factors
• Headache and gastrointestinal disturbances
🧪 Regular Follow-up
📌 Complete blood count
📌 Liver enzymes
📌 Blood lipids
📌 Tuberculosis screening before starting treatment
📌 Regular monitoring for any signs of infection
🧠 Overall
Tofacitinib is not a pain reliever, but a smart, targeted therapy that has proven in major clinical trials its ability to reduce disease activity, improve function, and achieve remission in several autoimmune diseases, with the advantage of being an effective oral treatment.
🩺 The right patient selection + good follow-up = excellent results, God willing.
If you liked this post, share it and subscribe to our page.
